Emerging role of 18F-FDG PET/CT in Castleman disease: a review

Insights into Imaging

David C. Fajgenbaum¹  Johnson S. Khor¹  Mark-Avery Tamakloe¹  Sheila K. Pierson¹  Abass Alavi²  Joseph Tran²  Sayuri Padmanabhan²  Thomas J. Werner²  Chaitanya Rojulpote²  Mahmoud Aly²  Vincent Zhang²  Mona-Elisabeth Revheim³  Benjamin Koa⁴  Austin J. Borja⁵ 

[1] Department of Medicine, Division of Translational Medicine and Human Genetics, University of Pennsylvania, Philadelphia, PA, USA;Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA;Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA;Division of Radiology and Nuclear Medicine, Oslo University Hospital, Sognsvannsveien 20, 0372, Oslo, Norway;Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Problemveien 7, 0316, Oslo, Norway;Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA;Drexel University College of Medicine, Philadelphia, PA, USA;Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA;Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA;

关键词: Castleman disease;    Positron emission tomography/computed tomography;    Fluorodeoxyglucose F18;    Interleukin-6;    HIV;   

DOI  :  10.1186/s13244-021-00963-1

来源: Springer

【 摘 要 】

Castleman disease (CD) describes a group of rare hematologic conditions involving lymphadenopathy with characteristic histopathology and a spectrum of clinical abnormalities. CD is divided into localized or unicentric CD (UCD) and multicentric CD (MCD) by imaging. MCD is further divided based on etiological driver into human herpesvirus-8-associated MCD, POEMS-associated MCD, and idiopathic MCD. There is notable heterogeneity across MCD, but increased level of pro-inflammatory cytokines, particularly interleukin-6, is an established disease driver in a portion of patients. FDG-PET/CT can help determine UCD versus MCD, evaluate for neoplastic conditions that can mimic MCD clinico-pathologically, and monitor therapy responses. CD requires more robust characterization, earlier diagnosis, and an accurate tool for both monitoring and treatment response evaluation; FDG-PET/CT is particularly suited for this. Moving forward, future prospective studies should further characterize the use of FDG-PET/CT in CD and specifically explore the utility of global disease assessment and dual time point imaging.Trial registration ClinicalTrials.gov, NCT02817997, Registered 29 June 2016, https://clinicaltrials.gov/ct2/show/NCT02817997

【 授权许可】

CC BY